Silence Therapeutics (NASDAQ:SLN) Issues Earnings Results

Silence Therapeutics (NASDAQ:SLN) released its earnings results on Thursday. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.13), FiscalAI reports. Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 106.94%.

Silence Therapeutics Stock Performance

SLN traded up $0.01 during trading on Thursday, hitting $19.77. The stock had a trading volume of 188,961 shares, compared to its average volume of 1,092,224. Silence Therapeutics has a twelve month low of $4.19 and a twelve month high of $19.86. The stock has a 50 day simple moving average of $14.46 and a two-hundred day simple moving average of $9.61. The company has a market capitalization of $1.23 billion, a PE ratio of -15.45 and a beta of 1.34.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on SLN shares. Jefferies Financial Group lowered Silence Therapeutics from a “buy” rating to a “hold” rating and set a $20.00 price target for the company. in a research note on Monday, October 19th. William Blair downgraded shares of Silence Therapeutics from an “outperform” rating to a “hold” rating in a report on Monday, October 19th. Chardan Capital cut shares of Silence Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 21st. Morgan Stanley raised their price target on Silence Therapeutics from $25.00 to $32.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 11th. Finally, HC Wainwright lowered shares of Silence Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $75.00 to $20.00 in a research report on Wednesday, October 21st. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $24.00.

About Silence Therapeutics

Silence Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce production of specific disease-related proteins. Its proprietary mRNAi GOLD platform is designed to create small interfering RNA (siRNA) medicines, including treatments that target genes expressed in the liver. The company’s research and development programs have included zerlasiran, which targets lipoprotein(a), a risk factor for cardiovascular disease, and divesiran, investigated for blood disorders.